CLINICAL_TRIALS
trial_result
· 2016-02-25
Clinical Trial Update: Study of Nivolumab (BMS-936558) Compared With Dacarbazine in Untreated, Unresectable, or Metastatic Melanoma [Phase 3]
Summary
Phase 3 trial comparing nivolumab to dacarbazine in untreated unresectable or metastatic melanoma completed with posted results.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Bristol-Myers Squibb | Conditions: Melanoma | Phase 3 | Status: COMPLETED | Results posted: 2016-02-25